HK1096583A1 - Cancer treatment using viruses and camptothecins - Google Patents
Cancer treatment using viruses and camptothecinsInfo
- Publication number
- HK1096583A1 HK1096583A1 HK07101289.1A HK07101289A HK1096583A1 HK 1096583 A1 HK1096583 A1 HK 1096583A1 HK 07101289 A HK07101289 A HK 07101289A HK 1096583 A1 HK1096583 A1 HK 1096583A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- virus
- camptothecins
- viruses
- cancer treatment
- treatment
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 241000711404 Avian avulavirus 1 Species 0.000 abstract 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 241000712079 Measles morbillivirus Species 0.000 abstract 1
- 241000700562 Myxoma virus Species 0.000 abstract 1
- 241000709664 Picornaviridae Species 0.000 abstract 1
- 241000710960 Sindbis virus Species 0.000 abstract 1
- 241000711975 Vesicular stomatitis virus Species 0.000 abstract 1
- 229940127093 camptothecin Drugs 0.000 abstract 1
- -1 camptothecin compound Chemical class 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 229960005395 cetuximab Drugs 0.000 abstract 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- 229960000303 topotecan Drugs 0.000 abstract 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56563104P | 2004-04-27 | 2004-04-27 | |
PCT/US2005/014144 WO2005113018A2 (en) | 2004-04-27 | 2005-04-26 | Cancer treatment using viruses and camptothecins |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1096583A1 true HK1096583A1 (en) | 2007-06-08 |
Family
ID=35428865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07101289.1A HK1096583A1 (en) | 2004-04-27 | 2007-02-02 | Cancer treatment using viruses and camptothecins |
Country Status (14)
Country | Link |
---|---|
US (3) | US20070207149A1 (ru) |
EP (1) | EP1744780B1 (ru) |
JP (2) | JP5170741B2 (ru) |
KR (1) | KR20070008710A (ru) |
CN (1) | CN1946421B (ru) |
AU (1) | AU2005244768B2 (ru) |
CA (1) | CA2562904C (ru) |
HK (1) | HK1096583A1 (ru) |
IL (1) | IL178492A (ru) |
MX (1) | MXPA06012145A (ru) |
NZ (1) | NZ550430A (ru) |
RU (2) | RU2408387C2 (ru) |
WO (1) | WO2005113018A2 (ru) |
ZA (1) | ZA200608119B (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1946421B (zh) * | 2004-04-27 | 2013-07-17 | 威尔斯达特生物制剂公司 | 使用病毒和喜树碱进行的癌症治疗 |
KR101479093B1 (ko) * | 2005-03-07 | 2015-01-26 | 로바츠 리서치 인스티튜트 | M135r 결핍 점액종 바이러스 및 이의 치료학적 용도 |
RU2435586C2 (ru) * | 2005-07-14 | 2011-12-10 | Веллстат Байолоджикс Корпорейшн | Лечение рака с применением вирусов, фторпиримидинов и камптотецинов |
WO2007143548A2 (en) | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Myxoma virus mutants for cancer treatment |
US20090317456A1 (en) * | 2006-10-13 | 2009-12-24 | Medigene Ag | Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer |
US20110318430A1 (en) * | 2008-12-18 | 2011-12-29 | New York University | Tumor therapy with antitumor agents in combination with sindbis virus-based vectors |
EP2327764B1 (en) | 2009-11-30 | 2011-12-28 | United Cancer Research Institute | New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer |
RU2456002C1 (ru) * | 2011-03-16 | 2012-07-20 | Алексей Владимирович Дубищев | Мочегонное средство |
WO2015023552A1 (en) * | 2013-08-13 | 2015-02-19 | Bionumerik Pharmaceuticals, Inc. | Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types |
CN107669707A (zh) * | 2017-11-16 | 2018-02-09 | 邹罡 | 埃可病毒作为溶瘤病毒在抗肿瘤中的应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019790A (ja) * | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
US5004758A (en) | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
DK1314431T3 (da) | 1993-04-30 | 2008-11-10 | Wellstat Biologics Corp | Oprensede sammensætninger af Newcastle disease virus |
US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
WO1997012623A1 (en) * | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
EA001400B1 (ru) | 1995-11-02 | 2001-02-26 | Глаксо Веллкам Инк. | Способ получения производных камптотецина |
GB9600438D0 (en) | 1996-01-10 | 1996-03-13 | Pharmacia Spa | Hexacyclic camptothecin analogues, and process for preparing them |
GB9601779D0 (en) | 1996-01-30 | 1996-04-03 | Pharmacia Spa | 9, 10 Disubstituted camptothecin derivatives |
GB9702807D0 (en) | 1997-02-12 | 1997-04-02 | Pharmacia & Upjohn Spa | Alkynyl-substituted camptothecins and process for their preparation |
GB9715821D0 (en) | 1997-07-25 | 1997-10-01 | Pharmacia & Upjohn Spa | Amidino-camptothecin derivatives |
GB9721070D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Bioactive derivatives of camptothecin |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
NZ509859A (en) * | 1998-08-05 | 2003-09-26 | Aventis Pharma S | Use of camptothecin derivatives, with reduced gastrointestinal toxicity |
SI1044977T1 (en) | 1999-03-09 | 2002-08-31 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Camptothecin derivatives having antitumor activity |
AU2905199A (en) * | 1999-03-15 | 2000-10-04 | Trustees Of The University Of Pennsylvania, The | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
EP1390046A4 (en) * | 1999-04-15 | 2005-04-20 | Wellstat Biologics Corp | TREATMENT OF NEOPLASMS WITH VIRUSES |
WO2000066125A1 (en) * | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
CN100532559C (zh) * | 2000-02-02 | 2009-08-26 | 安增子摩祺株式会社 | 用于基因转移的病毒包膜载体 |
EP1261341A2 (en) | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
BR0109272A (pt) | 2000-03-17 | 2004-06-29 | Cell Therapeutics Inc | Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos |
US6911200B2 (en) * | 2000-03-24 | 2005-06-28 | Cell Genesys, Inc. | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
GB0008928D0 (en) | 2000-04-11 | 2000-05-31 | Pharmacia & Upjohn Spa | A method of administering an antitumour compound |
PT1307197E (pt) * | 2000-05-15 | 2006-08-31 | Celgene Corp | Composicoes para o tratamento do cancro compreendendo um inibidor de topoisomerase e talidomida |
EP1286678A2 (en) * | 2000-06-01 | 2003-03-05 | Sloan-Kettering Institute For Cancer Research | Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
AR035227A1 (es) * | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
DE10133394A1 (de) * | 2001-07-13 | 2003-01-30 | Merck Patent Gmbh | Flüssige Formulierung enthaltend Cetuximab |
JP2005505526A (ja) * | 2001-07-23 | 2005-02-24 | エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト | Ugt1a1に基づいたがんの改善治療の手段及び方法 |
JPWO2003014338A1 (ja) * | 2001-08-02 | 2004-11-25 | アンジェスMg株式会社 | 不活性化ウイルスエンベロープの製造方法 |
WO2005113013A2 (en) | 2004-05-20 | 2005-12-01 | Theravir Management L.P. | Compositions of ndv and methods of use thereof for treatment of cancer |
US7615209B2 (en) * | 2001-09-12 | 2009-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions of NDV and methods of use thereof for treatment of cancer |
IL145397A0 (en) | 2001-09-12 | 2002-06-30 | Yissum Res Dev Co | Compositions and methods for treatment of cancer |
TW200306314A (en) | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
US6593334B1 (en) | 2002-05-02 | 2003-07-15 | The University Of North Carolina At Chapel Hill | Camptothecin-taxoid conjugates as antimitotic and antitumor agents |
ITRM20020306A1 (it) | 2002-05-31 | 2003-12-01 | Sigma Tau Ind Farmaceuti | Esteri in posizione 20 di camptotecine. |
WO2003101998A1 (en) | 2002-06-03 | 2003-12-11 | California Pacific Medical Center | Nitrogen-based homo-camptothecin derivatives |
AU2003243397A1 (en) | 2002-06-03 | 2003-12-19 | California Pacific Medical Center | Homo-camptothecin derivatives |
CA2489523A1 (en) | 2002-06-21 | 2003-12-31 | Wellstat Biologics Corporation | Administration of therapeutic viruses |
US6759416B2 (en) | 2002-08-06 | 2004-07-06 | Panorama Research, Inc. | Anticancer conjugates of camptothecin and unsaturated fatty acids |
US7427395B2 (en) * | 2002-11-01 | 2008-09-23 | Genomidea Inc. | Chemotherapeutic agent-incorporated pharmaceutical preparation |
CN1946421B (zh) | 2004-04-27 | 2013-07-17 | 威尔斯达特生物制剂公司 | 使用病毒和喜树碱进行的癌症治疗 |
EP1771174A1 (en) | 2004-05-28 | 2007-04-11 | Pfizer Products Inc. | Method for treating abnormal cell growth |
RU2435586C2 (ru) | 2005-07-14 | 2011-12-10 | Веллстат Байолоджикс Корпорейшн | Лечение рака с применением вирусов, фторпиримидинов и камптотецинов |
-
2005
- 2005-04-26 CN CN2005800130396A patent/CN1946421B/zh not_active Expired - Fee Related
- 2005-04-26 CA CA2562904A patent/CA2562904C/en not_active Expired - Fee Related
- 2005-04-26 NZ NZ550430A patent/NZ550430A/en not_active IP Right Cessation
- 2005-04-26 AU AU2005244768A patent/AU2005244768B2/en not_active Ceased
- 2005-04-26 RU RU2006141654/14A patent/RU2408387C2/ru not_active IP Right Cessation
- 2005-04-26 WO PCT/US2005/014144 patent/WO2005113018A2/en active Application Filing
- 2005-04-26 US US11/568,228 patent/US20070207149A1/en not_active Abandoned
- 2005-04-26 JP JP2007510862A patent/JP5170741B2/ja not_active Expired - Fee Related
- 2005-04-26 MX MXPA06012145A patent/MXPA06012145A/es active IP Right Grant
- 2005-04-26 KR KR1020067024721A patent/KR20070008710A/ko not_active Application Discontinuation
- 2005-04-26 EP EP05779961.1A patent/EP1744780B1/en not_active Not-in-force
-
2006
- 2006-09-29 ZA ZA2006/08119A patent/ZA200608119B/en unknown
- 2006-10-05 IL IL178492A patent/IL178492A/en not_active IP Right Cessation
-
2007
- 2007-02-02 HK HK07101289.1A patent/HK1096583A1/xx not_active IP Right Cessation
-
2010
- 2010-09-21 RU RU2010138887/15A patent/RU2010138887A/ru not_active Application Discontinuation
-
2012
- 2012-11-30 JP JP2012262340A patent/JP2013047276A/ja not_active Withdrawn
-
2013
- 2013-11-11 US US14/076,485 patent/US20140065140A1/en not_active Abandoned
-
2016
- 2016-06-28 US US15/195,200 patent/US9844574B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2005113018A2 (en) | 2005-12-01 |
NZ550430A (en) | 2009-06-26 |
CN1946421A (zh) | 2007-04-11 |
IL178492A (en) | 2010-06-30 |
RU2408387C2 (ru) | 2011-01-10 |
IL178492A0 (en) | 2007-02-11 |
WO2005113018A3 (en) | 2006-03-02 |
US20070207149A1 (en) | 2007-09-06 |
CA2562904C (en) | 2013-07-02 |
JP5170741B2 (ja) | 2013-03-27 |
AU2005244768B2 (en) | 2011-06-09 |
JP2007534761A (ja) | 2007-11-29 |
EP1744780A2 (en) | 2007-01-24 |
RU2006141654A (ru) | 2008-06-27 |
JP2013047276A (ja) | 2013-03-07 |
CA2562904A1 (en) | 2005-12-01 |
ZA200608119B (en) | 2008-05-28 |
CN1946421B (zh) | 2013-07-17 |
AU2005244768A1 (en) | 2005-12-01 |
RU2010138887A (ru) | 2012-03-27 |
US9844574B2 (en) | 2017-12-19 |
EP1744780B1 (en) | 2013-08-07 |
KR20070008710A (ko) | 2007-01-17 |
MXPA06012145A (es) | 2007-01-31 |
EP1744780A4 (en) | 2009-08-05 |
US20160303175A1 (en) | 2016-10-20 |
US20140065140A1 (en) | 2014-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1096583A1 (en) | Cancer treatment using viruses and camptothecins | |
IL186730A0 (en) | Cancer treatment using viruses, fluoropyrimidines and camptothecins | |
JP2018522027A5 (ru) | ||
ATE516819T1 (de) | Verfahren zur behandlung von b-zell-bedingtem krebs | |
HK1094167A1 (en) | Monoclonal antibodies to hepatocyte growth factor | |
CY1113287T1 (el) | Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα | |
PT933993E (pt) | Compostos de ciclopentano substituidos, uteis como inibidores de neuraminidase | |
RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
SI2579894T1 (en) | CGRP PROTITELESA | |
FI3083694T3 (fi) | Kaninisoituja hiiren anti-koira-pd-1 -vasta-aineita | |
WO2007084413A3 (en) | Methods for treating hepatitis c | |
DE602006021142D1 (de) | Verfahren zur behandlung von gefitinib-resistentem krebs | |
EA200100954A1 (ru) | Производные камптотецина, обладающие противоопухолевой активностью | |
JP2012523417A5 (ru) | ||
FI3355919T3 (fi) | Yhdistelmähoito ihmisen kasvu- ja erilaistumistekijä 15:n (GDF-15) inhibiittoreita ja immuunitarkistuspiste-estäjiä käyttämällä | |
WO2010047830A3 (en) | Agents for hcv treatment | |
NZ592436A (en) | Treatment with anti-alpha2 integrin antibodies | |
TW200507840A (en) | Method of treating multiple myeloma | |
SG156658A1 (en) | Treatment of diseases | |
EP3848389A4 (en) | SPECIFIC MONOCLONAL ANTIBODY AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HSRV) N ANTIGEN, USEFUL FOR INFECTION TREATMENT, DETECTION AND DIAGNOSIS | |
AR095364A1 (es) | Anticuerpos humanos de la proteína f del virus respiratorio sincitial y métodos de uso de estos | |
EA200870603A1 (ru) | Лечение опухолей у педиатрических пациентов антагонистами рецептора эпидермального фактора роста | |
WO2010096289A3 (en) | Combination therapy using an anti-egfr agent(s) and igf-1r specific antibodies | |
RU2019129614A (ru) | Антитела к b7-h1 и к ctla-4 для лечения немелкоклеточного рака легкого | |
IN2015DN00625A (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170426 |